KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials.

Anna Passera, Elisa Muscianisi, David Demanse, Ginette A Okoye, Gregor B E Jemec, Tiffany Mayo, Jennifer Hsiao, Vivian Y Shi, Angel S Byrd, Xiaoling Wei, Lorenz Uhlmann, Marc Vandemeulebroecke, Shoba Ravichandran, Martina L Porter

J Eur Acad Dermatol Venereol 39(8) 1410-1420

PMID39101698
PMCIDPMC12290999
DOI10.1111/jdv.20234
发表日期2024-08-05
入排依据:未发现恶性肿瘤人群证据。
已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 multi panel km;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。
摘要

摘要

BACKGROUND: Defining hidradenitis suppurativa (HS) subtypes was previously limited by small sample sizes and poor interrater reliability; no study has investigated subtype treatment responses. The objective of this analysis was to characterize HS clusters in adult patients with moderate to severe HS and evaluate secukinumab treatment responses between clusters. METHODS: Clusters were identified via an unsupervised machine learning clustering analysis using baseline data from the randomized, placebo-controlled SUNSHINE (NCT03713619) and SUNRISE (NCT03713632) phase 3 trials. To assess treatment responses, patients received secukinumab every 2 (SECQ2W) or 4 weeks (SECQ4W) or placebo, for 16 weeks, after which, placebo patients randomly switched to SECQ2W/SECQ4W, and SECQ2W/SECQ4W patients maintained their original treatment, until week 52. Baseline outcomes included patient characteristics, disease characteristics and severity, HS-associated comorbidities and previous treatment exposures. Treatment response was assessed via the HS clinical response (HiSCR), abscess and inflammatory nodule (AN) count, flares and NRS30 (skin pain). RESULTS: Based on baseline data, three clusters were identified from 1084 patients (Cluster 1: 54.1%, Cluster 2: 17.8%, Cluster 3: 28.1%). Cluster 1 was predominantly female (65.4%) and was characterized by milder HS. Cluster 2 had more patients from the Asia Pacific, Middle East and Africa region (58.5%) and was characterized by moderate HS. Cluster 3 had the highest rates of previous exposure to biologics (45.9%) and prior HS-related surgeries (47.5%) and was characterized by severe HS. SECQ2W and SECQ4W demonstrated efficacy versus placebo in all clusters at week 16; SECQ2W and SECQ4W efficacy was maintained to week 52. SECQ2W treatment showed a trend for greater efficacy versus SECQ4W in Cluster 3 through week 52. CONCLUSIONS: Three HS clusters were identified. Secukinumab demonstrated benefit over placebo in all clusters. However, patients with more severe disease may take longer to respond and more frequent secukinumab dosing may be required for these patients. TRIAL REGISTRATION: SUNSHINE (NCT03713619) and SUNRISE (NCT03713632).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Baseline subtype clusters of patients with HS identified during the subtype cluster analysis. Note : Hierarchical clustering on principal component analysis plot using baseline variables detailing the three clusters identified. Dim 1 [11.0%] and Dim 2 [6.4%] are the two principal components with the largest eigenvalues. Dim, dimension; HS, hidradenitis suppurativa.
非 KM Figure
FIGURE 2FIGURE 2 The effects of SECQ2W and SECQ4W on HiSCR, AN count, flares and NRS30 in Cluster 1. Line graphs showing the effects of SECQ2W and SECQ4W on (a) the proportion of patients achieving HiSCR, (b) mean CFB in AN count, (c) the proportion of patients experiencing flares and (d) the proportion of patients achieving NRS30 in Cluster 1 from baseline to week 52 in the SUNSHINE and SUNRISE trials. Data from baseline to week 52 are based on observed data. The numbers below each figure panel represent the number of evaluable patients at each respective timepoint. Error bars represent 95% confidence intervals. AN, abscess and inflammatory nodule; CFB, change from baseline; HiSCR, hidradenitis suppurativa clinical response; NRS, numeric rating scale; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg.
非 KM Figure
FIGURE 3FIGURE 3 The effects of SECQ2W and SECQ4W on HiSCR, AN count, flares and NRS30 in Cluster 2. Line graphs showing the effects of SECQ2W and SECQ4W on (a) the proportion of patients achieving HiSCR, (b) mean CFB in AN count, (c) the proportion of patients experiencing flares and (d) the proportion of patients achieving NRS30 in Cluster 2 from baseline to week 52 in the SUNSHINE and SUNRISE trials. Data from baseline to week 52 are based on observed data. The numbers below each figure panel represent the number of evaluable patients at each respective timepoint. Error bars represent 95% confidence intervals. AN, abscess and inflammatory nodule; CFB, change from baseline; HiSCR, hidradenitis suppurativa clinical response; NRS, numeric rating scale; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg.
非 KM Figure
FIGURE 4FIGURE 4 The effects of SECQ2W and SECQ4W on HiSCR, AN count, flares and NRS30 in Cluster 3. Line graphs showing the effects of SECQ2W and SECQ4W on (a) the proportion of patients achieving HiSCR, (b) mean CFB in AN count, (c) the proportion of patients experiencing flares and (d) the proportion of patients achieving NRS30 in Cluster 3 from baseline to week 52 in the SUNSHINE and SUNRISE trials. Data from baseline to week 52 are based on observed data. The numbers below each figure panel represent the number of evaluable patients at each respective timepoint. Error bars represent 95% confidence intervals. AN, abscess and inflammatory nodule; CFB, change from baseline; HiSCR, hidradenitis suppurativa clinical response; NRS, numeric rating scale; Q2W, every 2 weeks; Q4W, every 4 weeks; SEC, secukinumab 300 mg.
非 KM Figure